

FORM PTO-1390 (REV. 11-2000)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER 33944	
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371				U.S. APPLICATION NO. (If known, see 37 CFR 1.5) 09/937991	
INTERNATIONAL APPLICATION NO. PCT/JP00/02012		INTERNATIONAL FILING DATE 30 March 2000 (30.03.00)		PRIORITY DATE CLAIMED 02 April 1999 (02.04.99)	
TITLE OF INVENTION FUNCTIONALIZED GLYCOSAMINOGLYCAN POLYMER AND MEDICAL INSTRUMENTS AND DRUGS BY USING THE SAME					
APPLICANT(S) FOR DO/EO/US YURA, Hirofumi; SAITO, Yoshio; ISHIHARA, Masayuki; ONO, Katsuaki; ISHIKAWA, Keiichi					
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:					
<p>1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.</p> <p>2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.</p> <p>3. <input type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.</p> <p>4. <input checked="" type="checkbox"/> The US has been elected by the expiration of 19 months from the priority date (Article 31).</p> <p>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2))</p> <p>a. <input type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau).</p> <p>b. <input checked="" type="checkbox"/> has been communicated by the International Bureau.</p> <p>c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).</p> <p>6. <input checked="" type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).</p> <p>a. <input checked="" type="checkbox"/> is attached hereto.</p> <p>b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4).</p> <p>7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))</p> <p>a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau).</p> <p>b. <input type="checkbox"/> have been communicated by the International Bureau.</p> <p>c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.</p> <p>d. <input checked="" type="checkbox"/> have not been made and will not be made.</p> <p>8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).</p> <p>9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).</p> <p>10. <input type="checkbox"/> An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</p> <p>Items 11 to 20 below concern document(s) or information included:</p> <p>11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</p> <p>12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</p> <p>13. <input type="checkbox"/> A FIRST preliminary amendment.</p> <p>14. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.</p> <p>15. <input type="checkbox"/> A substitute specification.</p> <p>16. <input type="checkbox"/> A change of power of attorney and/or address letter.</p> <p>17. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.</p> <p>18. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4).</p> <p>19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).</p> <p>20. <input checked="" type="checkbox"/> Other items or information: English translation of Amendments Under Article 34 of PCT filed on October 27, 2000 English translation of Amendments Under Article 34 of PCT filed on March 30, 2001.</p>					

U.S. APPLICATION NO. (if known) 09/937991		INTERNATIONAL APPLICATION NO. PCT/JP00/02012		ATTORNEY'S DOCKET NUMBER 33944	
---	--	---	--	-----------------------------------	--

21. <input checked="" type="checkbox"/> The following fees are submitted: BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)): Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO..... \$1000.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$860.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$710.00 International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$690.00 International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) \$100.00 ENTER APPROPRIATE BASIC FEE AMOUNT =				CALCULATIONS PTO USE ONLY	
				\$	860.00
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input checked="" type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$	130.00
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$	
Total claims	6 - 20 =	0	x \$18.00	\$	-----
Independent claims	1 - 3 =	0	x \$80.00	\$	-----
MULTIPLE DEPENDENT CLAIM(S) (if applicable)				+	\$270.00
TOTAL OF ABOVE CALCULATIONS =				\$	1,260.00
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.				+	\$630.00
SUBTOTAL =				\$	630.00
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$	-----
TOTAL NATIONAL FEE =				\$	630.00
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +				\$	-----
TOTAL FEES ENCLOSED =				\$	630.00
				Amount to be refunded:	\$
				charged:	\$

a. ☒ A check in the amount of \$ 630.00 to cover the above fees is enclosed.


b. ☐ Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees.
 A duplicate copy of this sheet is enclosed.


c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any
 overpayment to Deposit Account No. 16-0820. A duplicate copy of this sheet is enclosed.
 Order no. 33944


d. ☐ Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. **Credit card
 information should not be included on this form.** Provide credit card information and authorization on PTO-2038.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR
 1.137 (a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:


00116
PATENT & TRADEMARK OFFICE


SIGNATURE
Jeffrey J. Sopko
NAME
27676
REGISTRATION NUMBER



5020

09937991 017300
JC02 Rec'd PCT/PTO 25 MAR 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Hirofumi Yura et al.
Serial No.: 09/937,991
Filing Date: September 28, 2001
Title: FUNCTIONALIZED GLYCOSAMINOGLYCAN POLYMER
AND MEDICAL INSTRUMENTS AND DRUGS BY USING
THE SAME
Docket No.: 33944

PRELIMINARY AMENDMENT

Box AMENDMENTS
Commissioner for Patents
Washington, D.C. 20231

Dear Sir/Madam:

Please amend the above-referenced application prior to its examination as follows.


I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231 on the date indicated below.

John P. Muntough
Name of Attorney for Applicant(s)
3-14-02 John P. Muntough
Date Signature of Attorney

IN THE CLAIMS:

Please add new claims 7-10 as follows:

Claim 7. (New) An agent for preventing reconstriction of a blood vessel comprising a functionalized polymer, said functionalized polymer having a structure represented by the following formula (1):



wherein, W denotes a carbohydrate chain including a structure corresponding to at least a portion of the basic skeletal structure of a glycosaminoglycan and comprising 2-50 constituent disaccharide units having an average of at least one sulfate group, X, Y and Z denotes any substituent group including a hydrogen atom, and n denotes the number of repeating unit of at least 1.

Claim 8. (New) The agent of claim 7, characterized in that said carbohydrate chain is a decomposed carbohydrate chain obtained by chemical decomposition of a natural glycosaminoglycan, and said decomposed carbohydrate chain is bonded to the polymer main chain via a functional group formed by said chemical decomposition.

Claim 9. (New) The agent of claim 7, characterized in that said glycosaminoglycan is heparin/heparan sulfate, chondroitin sulfate, dermatan sulfate or a partially desulfated modification thereof.

Claim 10. (New) The agent of claim 8, characterized in that said glycosaminoglycan is heparin/heparan sulfate, chondroitin sulfate, dermatan sulfate or a partially desulfated modification thereof.

REMARKS

New claims 7-10 have been added. These new claims are clearly supported by the specification (for example, page 10, lines 17-20) and Example 8 (page 19, line 16 to page 20, line 17). No new matter has been entered by these amendments.

If any fees are required by this communication, please charge such fees to our Deposit Account No. 16-0820, Order No. 33944.

Respectfully submitted,
PEARNE & GORDON LLP

By: John P. Murtaugh
John P. Murtaugh, Reg. No. 34226

526 Superior Avenue East
Suite 1200
Cleveland, Ohio 44114-1484
(216)579-1700

March 14, 2002

3/PATS

09937991.012302

09/937991

JCO9 Rec'd PCT/PTO 28 SEP 2001

SPECIFICATION

5

FUNCTIONALIZED GLYCOSAMINOGLYCAN POLYMER AND MEDICAL INSTRUMENTS AND DRUGS BY USING THE SAME

FIELD OF THE INVENTION

The present invention relates to a novel polymeric material formed by incorporating into a vinyl polymer the structure of glycosaminoglycans which are natural polysaccharides that bind with various cell growth factors and cytokines to control cell proliferation, and its application to medicine.

BACKGROUND ART

The acidic polysaccharide group known as glycosaminoglycans (GAG) including heparin/heparan sulfate (HS), chondroitin sulfate, dermatan sulfate, keratan sulfate and hyaluronic acid attach to core proteins by means of covalent bonds, forming proteoglycans (PG) which are present in connective tissue and cell membranes. PG's, along with other cell-adhesive proteins, form the extracellular matrix, and are widely distributed in order to enable cells to live and to perform biological functions. In particular, heparan sulfate proteoglycans (HS-PG) are present in the tissue of almost all animals, and perform the extremely important functions of cell adhesion, morphogenesis and maintenance of functions.

Additionally, it has become clear that heparin/HS contained in PG's interacts with various types of cell growth factors and plays a considerable role in the control of

cell differentiation and proliferation. Fibroblast growth factors (FGF) form the FGF family (currently, FGF1-FGF10 are known) having a high affinity with heparin/HS, and act with specificity with respect to vascular endothelial cells, Kaposi's sarcoma cells and epidermal keratinocytes. Such activity of FGF's is believed to occur as a result of

5 binding specifically to FGF receptors (FGFR) on the cell surface. That is, as shown schematically in Fig. 1, heparin/HS pierces the membrane holds and preserves unstable FGF molecules in a stable state in the vicinity of the cell, and supports FGF bonds to the receptors (FGFR) on the cells as needed while protecting the FGF from proteolytic enzymes and oxidative decomposition. The FGF bonding to the FGFR causes the

10 proliferation signal to be transmitted and promotes cell proliferation. This mechanism has been proven by much research which suggests that FGF's and FGFR's cannot bind without the presence of heparin/HS (for example, see M. Ishihara, *Glycobiology*, 4, 817-824 (1994)).

Heparin/HS is composed of a repeating structure of disaccharides including

15 uronic acid having a carboxymethyl group and glucosamin having an acetyl group, and an important characteristic is the sulfation of hydroxyl groups and amino groups present in the molecule in various proportions. About 10 types of sulfation of the disaccharides have been identified, and heparin and HS are divided depending on differences in the sulfation. Additionally, cells are believed to control the activity of the

20 FGF family by themselves preparing various types of heparin/HS of different levels of sulfation and molecular chain lengths according to their type and state.

Aside from controlling the activity of FGF, heparin/HS, which can take various

On the other hand, the various functions of heparin/HS are known to change dramatically according to the molecular chain length. For example, while antithrombin III which inhibits blood coagulation binds with a characteristic structural domain having a 3-O-sulfate group contained in heparin/HS, a sequence of at least 5 saccharides is necessary to express this anti-coagulant activity, so that in actual practice, smaller molecules make reduced activity inevitable. Additionally, in order to ensure expression of FGF1 and FGF4 activity, a structural domain of at least 10 saccharides containing an abundance of 2- O-sulfate groups and 6-O-sulfate groups is necessary.

-3-

Furthermore, in order to apply GAGs containing heparin/HS to various fields, they must be efficiently attached to hydrophobic resin products commonly used in the medical field such as polystyrenes and polycarbonates, but GAGs and their fragments generally have a high water solubility and are difficult to adsorb and attach firmly to the various resin products so that, for example, it is difficult to apply GAGs to diagnostic beads or culture dishes in order to make them useful for general basic medical research or clinical medicine.

10 SUMMARY OF THE INVENTION

As a result of repeatedly performing diligent research to solve the
above-described problems, the present inventors discovered that by means of a
functionalized polymer characterized by incorporating a carbohydrate chain containing
15 a structure corresponding to at least a portion of a basic glycosaminoglycan skeletal
structure into a vinyl polymer main chain, it is possible to adequately activate desired
activity without side effects, and especially to enable the adhesion and fixation to
hydrophobic resin products used in the medical field with ease and at a high density.

The structure of the functionalized polymer of the present invention takes a vinyl polymer as the main chain, and incorporates a carbohydrate chain containing a structure corresponding to at least a portion of the basic skeletal structure of a glycosaminoglycan (GAG) on this main chain. That is, the functionalized polymer of the present invention includes at least one, preferably a plurality of active GAG domains

in a single molecule, whereby the interaction of biological activity of these active domains, particularly in the case of heparin/HS, is more greatly reinforced with respect to various cell growth factors and cytokines.

Additionally, the present invention also offers a medical instrument with the surface modified by means of such functionalized polymers. Since these types of medical instruments have GAGs affixed to the surface, they are useful, for example, for cell culture and diagnosis equipment.

Furthermore, the functionalized polymers of the present invention also offer a drug based on the cell growth inhibiting effect of GAGs, particularly a cell growth
10 controlling agent, more specifically including anti-tumor agents.

BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 is a schematic diagram for explaining the mechanism of cell proliferation.

Fig. 2 is a schematic diagram showing an example of the functional mechanism of an anti-tumor agent of the present invention.

Fig. 3 is a graph showing a gel filtration pattern for Example 1.

Fig. 4 is a graph showing the adsorption of functionalized polymers of the present invention for Example 2.

Fig. 5 is a graph showing the adhesion of cell growth factor through the functionalized polymers of the present invention for Example 3.

PREFERRED MODE FOR CARRYING OUT THE INVENTION

Herebelow, the functionalized polymers of the present invention shall be

described in further detail.

The vinyl polymer used as the main chain in the functionalized polymer of the present invention may be any homopolymer or copolymer composed of a polymerizable monomer, which can for example be selected arbitrarily from the addition
 5 polymerization type, condensation polymerization type, polyaddition type, addition condensation type and open circular type monomers described in the *Chemical Handbook* (Applied Chemistry Edition 1, Chemical Society of Japan, Maruzen, 1987), and is not particularly restricted. Preferably, it should be a polymer of an addition polymerizable monomer having at least one unsaturated bond, such as ethylene, propylene, styrene,
 10 vinyl acetate, acrylic acid or acrylamide, and these can be arbitrarily substituted.

A carbohydrate chain containing a structure corresponding to at least one portion of a basic glycosaminoglycan skeletal structure is bonded to this main polymer chain. That is, the functionalized polymer of the present invention contains at least one unit expressed by the following general formula (1).



In the above formula, W denotes a carbohydrate chain, X, Y and Z denote arbitrary substituent groups containing hydrogen atoms, and n denotes the number of repeating units of at least 1.

The carbohydrate chain composing the functionalized polymer of the present
 20 invention has a structure corresponding to at least a portion of the basic skeletal structure forming GAGs such as heparin/HS, chondroitin sulfate, dermatan sulfate and keratan sulfate, the number of constituent disaccharide units being at least 2-50, more

and alginic acid, incorporating sulfate groups by enzymes or chemical synthesis.

The chemical decomposition of the natural glycosaminoglycans described above can be performed favorably by severing the carbohydrate chain bonds in the above-described polysaccharides using nitrous acid or periodic acid under

5 non-physiological conditions outside the range of pH 6.5-8.0, preferably the acidic and/or alkaline regions of less than pH 5 or more than pH 10, thereby obtaining a fractionated carbohydrate chain. Additionally, it is also possible to use fractionated carbohydrate chains such as those obtained by enzymatic decomposition with enzymes which selectively decompose carbohydrate chains such as heparinase, heparitinase,

10 chondroitinase and keratanase, or those decomposed by heat, plasma discharge, or those chemically decomposed by radical reactive reagents.

The carbohydrate chain in the functionalized polymer of the present invention binds to the polymer main chain by means of covalent bonds. The nature of these bonds is not particularly restricted, and they can be made by coupling together their

15 functional groups using any catalyst under suitable reaction conditions according to the combinations of functional groups possessed by the polymer main chain and carbohydrate chain. Additionally, while it is possible to form a carbohydrate chain-derived monomer by binding a monomer constituting the polymer main chain with a carbohydrate chain, the carbohydrate chain-derived monomer should preferably

20 be polymerized so as to be able to adjust the carbohydrate content in a single molecule. Among these, a functionalized polymer obtained by incorporating a fractionated hydrophilic carbohydrate chain into a hydrophobic monomer unit and polymerizing the

The incorporation of carbohydrate chains in the functionalized polymer of the present invention can be performed, for example, by a Schiff bonding of aldehyde groups or carbonyl groups formed on chemically decomposed GAGs with amino groups of the monomers constituting the polymer. Furthermore, coupling agents having acid chloride groups, N-hydroxysuccinic acid imide ester groups or epoxy groups are suitable for use as methods for binding vinyl monomers with the functional groups of the carbohydrate chains. In particular, a method of using aldehyde groups formed on the GAGs by means of chemical decomposition is more preferably used due to its convenience and ability to preserve the activity of the GAGs.

Accordingly, the functionalized polymer of the present invention, due to its hydrophobisity of the polymer main chain, adheres to the surface of hydrophobic resins such as polystyrenes, polycarbonates, polyamides, polysulfones and polyesters used in synthetic resin products that are commonly used in medical applications to thereby modify the surface, enabling the tissue compatibility and blood compatibility of the

cell growth factors, cytokines, vascular growth factors and FGFs which contribute to the proliferation of cancer cells in tumor tissue, thereby to inhibit the growth of cancer cells or vascular endothelial cells and suppress the growth of tumors. Hence, the present invention also offers a cell growth control agent composed of the above-described

5 functionalized polymer, particularly an anti-tumor agent (carcinostatic). For example, in hematic cancers such as acute lymphocytic leukemia or the like, some of the increased cancer cells are known to break off, create obstacles to blood flow and cause renal failure, and in such situations, heparin or the like is dripped intravenously to preserve the blood flow. At this time, a temporary reduction in blastogenesis of cancer cells is often

10 observed, and this effect is believed to be due to the proliferation controlling function of heparin. That is, the anti-tumor agent of the present invention which has a plurality of heparin-like active domains is clearly effective not only for solid cancers but also for the treatment of hematic cancers such as leukemia.

Specifically, since the functionalized polymer of the present invention has a

15 plurality of hydrophilic (water-soluble) carbohydrate chains bound to a hydrophobic polymer main chain, it is believed to exist in an aqueous solution with the polymer chain as a core, with the carbohydrate chains spread out in the vicinity thereof (Fig. 2, polyvinyl heparin (PV-heparin)). Therefore, a functionalized polymer having this type of structure (anti-tumor agent) is thought to be able to capture and absorb FGFs present

20 around the cells so as to inhibit their binding to receptors as shown schematically in Fig. 2. Consequently, the anti-tumor agent of the present invention is believed to be based not on toxicity with respect to the cells, but follows a new functional mechanism by

EXAMPLES

Herebelow, the present invention shall be described in further detail by means of examples.

Example 1: Synthesis of Polyvinyl Heparins

25 g of sodium heparin (Scientific Protein Laboratories, USA) were dissolved in 400 ml of an acetate buffer solution (0.1 M, pH5) containing periodic acid, then stirred for a few days at 5 °C or less. To this, 20 ml of glycerol were added, and after stirring for an additional few hours, the reaction solution was put under dialysis for 2 days for desalination. After recovering the reaction solution and adding sodium hydroxide to adjust to a pH of 7.5, 21 g of a reaction product was obtained. 10 g of this was separated out and formed into an aqueous solution adjusted to a pH of 12 by means of sodium hydroxide, which was then stirred for a few hours at room temperature. After performing a dialysis operation similar to that described above on the reaction solution, the low-molecular-weight heparins were fractioned out using a gel filtration column (Bio-Gel, Bio-Rad), and the carbazole assay of Bitter et al. (T. Bitter and H. A. Muir, *Anal. Biochem.*, 4, 330-334 (1962)) was used to obtain a periodic acid-decomposed heparin having 20 saccharides in a center of molecular weight distribution (hereinafter referred to as I-20).

1 g of the native sodium heparin was dissolved in water and adjusted its pH to not more than 2 with 1 N hydrochloric acid. 20 mg of sodium nitrite was added to the prepared heparin solution and allowed to react for 2 hours. After dialysis for 2 days, low-molecular-weight heparin was fractionated using a gel filtration column (Bio-Gel, Bio-Rad). The fractionated carbohydrate chains were quantitated by the above-described carbazole method to obtain nitrite decomposed heparins having 6, 8, 10, and 12 saccharides (hereinbelow, termed as N-6, N-8, N-10, and N-12, respectively).

A vinylbenzylamine was synthesized in accordance with the method of Kobayashi et al. (K. Kobayashi et al., *Polym. J.*, 17, 567-575 (1985)). 300 mg each of the resulting I-20, N-6, N-8, N-10 and N-12 were dissolved in respectively 10 ml of a tetraethylmethylenediamine buffer solution (TEMED, pH 5), and 300 mg of vinylbenzylamine were added to each TEMED solution. 30 mg of a sodium cyanoborohydride aqueous solution were added to the solution formulated in this way, and this was stirred for 24 hours at room temperature. The reaction solution was desalinated by means of dialysis, and after filtering out the undissolved part, the result was freeze-dried to obtain a carbohydrate chain (I-20, N-6, N-8, N-10 and N-12) derived vinyl monomer.

The resulting carbohydrate chain-derived vinyl monomer was dissolved in 3 ml of water, and 4 mg of potassium peroxodisulfate were added. After deaeration and nitrogen replacement, this was sealed and allowed to react overnight at 63 °C. The reaction solution was dripped into methanol to precipitate the product, after which the precipitate was filtered and recovered. The recovered substance was redissolved in

water and a dialysis was performed, the unreacted part was removed by ultrafiltration (YM10, fractionation molecular weight 10,000, Amicon), and freeze-dried to purify to obtain polyvinyl heparin (PV-heparin). These PV-heparins shall be referred to as P-I-20, P-N-6, P-N-8, P-N-10 and P-N-12.

5

Example 2: Synthesis of Polyvinylated N-Desulfated Heparin

10 20 g of heparin (pyridinium salts) were dissolved in a mixed solution of 20 ml of distilled water and 380 ml of dimethylsulfoxide (DMSO), and this was stirred for 90 minutes at 50 °C to react. 1 g of the heparin, which had been obtained by dialysis followed by lyophilization and were N-desulfated but preserving the O-sulfate, was dissolved in 30 ml of a sodium carbonate solution (50 mM) containing 10 wt% of methanol, and after adding 1 ml of acetic anhydride on ice, the pH was adjusted to 7-8 using sodium hydroxide. This operation was repeated 5 times at intervals of 30 minutes to form N-acetylated heparin, which was put under dialysis and freeze-dried.

15 This reaction product was polymerized based on acidification by periodic acid according to Example 1, thereby obtaining P-I-DSA 20 with an average of 20 saccharide chains.

Example 3: Synthesis of Polyvinylated Chondroitin Sulfate

20 0.5 g of chondroitin sulfate C (Seikagaku Kogyo, derived from shark cartilage) were dissolved in 5 ml of a hydrazine monohydrate containing 50 mg of hydrazinium sulfate, and this was allowed to react for 3.5 hours at 95 °C. The partially

hydrazine-decomposed product was put under dialysis for 1 day with flowing water, then freeze-dried, and the impurities removed by oxidation with a suitable amount of iodate. After putting under dialysis with flowing water for another 2 days and freeze-drying, the product was decomposed by nitrous acid in accordance with Example 1, to obtain P-N-20C with 20 saccharide chains.

Example 4: Synthesis of Polyvinylated Dermatan Sulfate

P-N-20D having 20 saccharide chains decomposed by nitrous acid was obtained in accordance with Example 3, with the exception of the fact that the 0.5 g of chondroitin sulfate C were replaced by dermatan sulfate.

The synthesis reaction of a PV-heparin monomer derived from a low-molecular-weight heparin was confirmed by a vinyl group-originating peak in ¹HNMR, and polymerization by homopolymerization of monomers was confirmed by broadening the peak of the ¹HNMR and molecular weight fractionation due to gel filtration. For example, a gel filtration of P-I-20, native heparin and acid decomposed I-20 using Bio-Gel P-100 (Bio-Rad) provided a fractionation in order of uniform polymerized P-I-20, native heparin and periodic acid-decomposed I-20. This type of gel filtration pattern was able to be confirmed for polyvinylated GAGs of all types (see Fig. 3).

Example 5: Adsorption onto Resin Products

Aqueous solution containing a predetermined concentration of P-I-20 or native heparin was added to a polystyrene 96-well multiplate (Sumitomo Bakelite), and the

carbohydrate concentration adhered to the polystyrene surface was evaluated after 24 hours using the above-mentioned carbazole method. The results are shown in Fig. 4.

As shown in Fig. 4, the polyvinylated heparin (P-I-20) of the present invention adhered efficiently to the polystyrene surface, while native heparin did not adhere to the resin surface. In addition, the other polyvinylated heparins, such as P-N-12, P-N-10, P-N-8, and P-N-6 were observed adhesion amounts of 20-80 $\mu\text{g/ml}$ at an addition concentration of 0.5 mg/ml. Furthermore, almost the same adhesion profiles were observed for polyvinylated N-desulfated heparin, polyvinylated chondroitin sulfate, and polyvinylated dermatan sulfate.

Furthermore, aside from polystyrene, similar adsorptive properties were observed in polycarbonates, polysulfones and polyurethanes. This indicates that the polyvinylated heparins of the present invention are an effective means of adsorbing and affixing heparin molecules to resin products for medical use. The functionalized polymers of the present invention also exhibited such efficient adsorption with respect to glass materials.

Example 6: Binding of Cell Growth Factor to Polyvinylated Heparin Coated Plate

100 μl of a phosphoric buffer solution (supplemented with 0.1% fetal bovine serum, pH 7.2) into which was dissolved a cell growth factor (FGF-2, HGF, VEGF 165) was added to a polystyrene 96-well multiplate (Sumitomo Bakelite) coated with the P-I-20 prepared in Example 1, and the binding ability of each cell growth factor was compared with untreated multiwells not coated with P-I-20.

As shown in Figs. 5(1), (2) and (3), in the dishes treated with the P-I-20 of the present invention, the added concentration of cell growth factor was confirmed to be at least 500 pg/0.1 ml, and coloration of the peroxidase based on binding of each growth factor was confirmed, but bonds were not observed in the untreated dishes. This indicates that the polyvinylated heparins of the present invention can specifically bind to various growth factors, and that the coloration based on the bonds of these growth factors was inhibited competitively by the addition of natural heparins. The above-given results indicate that the plates treated with the polyvinylated heparins of the present invention are able to detect cell growth factors and cytokines that increase with damage such as cancers or wounds easily and with high precision.

On the other hand, this type of characteristic growth factor binding activity was weak with polyvinylated N-desulfated heparin, polyvinylated chondroitin sulfates and polyvinylated dermatan sulfates.

Example 7: Cell Cultures on PV-Heparin Coated Tissue

A polystyrene 96-well multiplate was coated with aqueous P-I-20 or P-N-12

solutions (0.5 mg/ml) of the present invention, and also 2% gelatin and 10 µg/ml of human fibronectin solution, these were inoculated with 6,000 human coronary artery endothelial cells (CEC) suspended in a Dulbecco modified Eagle medium (10% fetal bovine serum added), after which FGF2 or VEGF165 were added as cell growth factors, and this was cultured from 3 days. After culturing, a WST-1 reagent (cell counting kit, Dojindo) was used to count the number of increased cells, and the results of an evaluation of the proliferation rate are shown in Table 1.

Table 1 CEC Proliferation Rate

Coating	Growth Factor			
	FGF2		VEGF165	
	4µg/l	8 µg/l	4µg/l	8 µg/l
None	229	286	190	195
P-I-20	392	408	364	404
P-N-12	409	426	360	414
Gelatin	356	389	335	385
Fibronectin	273	327	371	436

As shown in Table 1, the rate of proliferation of vascular endothelial cells with respect to growth factors in the polyvinylated heparins of the present invention is clearly at least the same as fibronectin which is a cell adhesive protein. This suggests that the polyvinylated heparins allowed the cell growth factors to be increased and stabilized on the mutiplate surface, thereby maintaining good cell proliferation.

Example 8: Inhibition of Cell Growth Factor by Polyvinylated Heparins

The cell growth factor-dependent CECs of Example 7 were suspended in a culture medium with FGF2 or VEGF15 added at a concentration of 5 ng/ml, and these

Next, the proliferation of smooth muscle cells (SMC) from the human coronary artery and mesangial cells (MGC) from the human kidney cultured under the same conditions as the above paragraph aside from not adding the two types of cell growth factor was studied. The results are shown in Table 3.

5 **Table 3** Concentration for Suppressing Growth Factor
Non-dependent Cell Proliferation by 45% ($\mu\text{g/ml}$)

Heparin-related Substance	Cell	
	FGF2	VEGF165
Native heparin	28	16
I-20	70	64
N-12	80	70
P-I-20	2	5
P-N-12	3	5

As shown in Table 3, the proliferation of smooth muscle cells and mesangial cells which are capable of proliferation without depending on the cell growth factor in
 10 an *in vitro* culture are also effectively suppressed by the addition of polyvinylated heparins. This type of high proliferation suppression effect is indicated to be due to the absorption not only of cell growth factors, but also substances contained in the culture medium and cytokines created upon proliferation of the cells by means of interaction with the polyvinylated heparins. The above results suggest that the
 15 polyvinylated heparins of the present invention can not only suppress the growth of tumors, but also can be materials for preventing reconstriction after PTCA in the vicinity of the circulatory organs.

Example 9: Tumor Growth Suppressing Effect

10⁶ murine colon cancer cells Colone 26 were injected subcutaneously into the flank portions of 6-8 week old BALB/C mice. After two weeks, the formation of tumors 5 mm in diameter was confirmed, and each was given a daily subcutaneous injection in the vicinity of the tumor of 0.1 ml each of only physiological saline solution in the case of 3 examples as a control, and physiological saline solution containing the P-I-14 of the present invention (10 mg/ml) for another 3 examples. A comparison of the growth of the tumors is shown in Table 4.

Table 4

Tumor Model Mice (Tumor Size 5 mm)	Condition of Tumor		
	after 1 week	after 2 weeks	after 3 weeks
Control Group	Tumor Size 10-12 mm	Tumor size 20 mm or more	Tumor Size 30 mm or more
P-I-20-administered Group	Tumor Size 6-7 mm	Tumor Size 10 mm	Tumor Size 15 mm or less
			Partial tumor necrosis

As shown in Table 4, the growth of tumors is effectively suppressed when the polyvinylated heparins of the present invention are administered. Furthermore, after 4 weeks, the control group entered a state of cancerous cachexia, extreme weight loss, paralysis of the hind legs and abnormalities in the fur were observed, and they exhibited seriously weakened conditions. In contrast, the overall condition of the group administered the polyvinylated heparins (P-I-20) of the present invention was extremely good. Additionally, in the administered group, the kidney functions and liver functions (creatinine, BUN, total bilirubin, GOT, GPT, total protein content in the blood) were no different from healthy mice, and no side effects considered to be due to

polyvinylated heparin administration were observed. The above results indicate that the polyvinylated heparins of the present invention can be used as anti-tumor agents (carcinostatics) for effectively suppressing tumors due to solid cancers.

5 **Example 10: Comparison of Interactions with Cells in Polyvinylated GAGs**

A comparison of cell adhesion on dishes coated with the polyvinylated GAGs according to the above-described examples was performed. In this case, in addition to mesangial cells, human skin fibroblasts (SFB) and keratinocytes (SKC) were added for comparison. Additionally, 10 ng/ml of hrFGF-2 was added to the CECs.

10 The proportion (%) of adhered cells among the inoculated cells after 6 hours is shown in Table 5.

Table 5

Coated Cell	P-I-20	P-N-12	P-I-DSA20	P-N-20C	P-N-20D
SFB	96	96	88	33	39
SMC	90	95	85	20	22
CEC	99	98	95	5	9
SKC	85	90	80	3	6

As shown in Table 5, the cell adhesion with respect to each type of functionalized glycosaminoglycan was such that the heparins exhibited high adhesion to each type of cell, but those which were N-desulfated were slightly more controlled than those which were not desulfated. On the other hand, the adhesion was strongly suppressed in chondroitin sulfate and dermatan sulfate.

In addition to the cell adhesion described above, cell culturing was performed over a period of 7 days, and the proliferation rate of the cells with respect to each

functionalized glycosaminoglycan was compared. The proliferation rate was evaluated by an OD₅₄₀ value based on a cell counting reagent. Table 6 compares the proliferation rate of the cells with respect to each material.

Table 6

Cell	Culture Period (days)	Cell Proliferation Rate (OD ₄₅₀) on Functionalized GAG				
		P-I-20	P-N-12	P-I-DSA20	P-N-20C	P-N-20D
SFB	1	0.15	0.16	0.04	0.04	0.08
	2	0.25	0.30	0.12	0.12	0.14
	4	0.72	0.82	0.15	0.15	0.25
	7	1.50	1.72	1.63	0.19	0.41
SMC	1	0.14	0.15	0.14	0.08	0.10
	2	0.22	0.23	0.22	0.12	0.18
	4	0.38	0.39	0.42	0.20	0.23
	7	0.41	0.43	0.74	0.25	0.33
CEC	1	0.11	0.12	0.10	0.02	0.02
	2	0.18	0.19	0.17	0.03	0.04
	4	0.32	0.36	0.31	0.03	0.07
	7	0.49	0.50	0.42	0.02	0.10
SKC	1	0.11	0.13	0.13	0.09	0.10
	2	0.18	0.20	0.21	0.12	0.12
	4	0.31	0.37	0.38	0.16	0.28
	7	0.64	0.76	0.81	0.34	0.58

5

As shown in Table 6, while the proliferation rate of fibroblasts, vascular endothelial cells and skin keratinocytes in the heparin type functionalized materials was high, the proliferation rate was low in dermatan sulfate and chondroitin sulfate type functionalized materials. This difference in proliferation rate indicates a high correlation with the adhesive ability with respect to each material. On the other hand, whereas heparin is known to have a suppressing effect on the proliferation of smooth muscle cells, the heparin type functionalized materials exhibited the same level of suppression of proliferation as the dermatan sulfate and chondroitin sulfate type

10

CLAIMS

1. (amended) A functionalized polymer having a structure represented by the following formula (1):



wherein, W denotes a carbohydrate chain including a structure corresponding to at least a portion of the basic skeletal structure of a glycosaminoglycan and comprising 2-50 constituent disaccharide units having an average of at least one sulfate group, X, Y and Z denotes any substituent group including a hydrogen atom, and n denotes the number of repeating unit of at least 1.

2. A functionalized polymer in accordance with claim 1, characterized in that said carbohydrate chain is a decomposed carbohydrate chain obtained by chemical decomposition of a natural glycosaminoglycan, and said decomposed carbohydrate chain is bonded to the polymer main chain via a functional group formed by said chemical decomposition.

3. A functionalized polymer in accordance with claim 1 or 2, characterized in that said glycosaminoglycan is heparin/heparan sulfate, chondroitin sulfate, dermatan sulfate or a partially desulfated modification thereof.

4. (deleted)

5. (amended) A medical instrument characterized by being surface-modified by a functionalized polymer in accordance with any one of claims 1-3.

Amendments Under Article 34 of PCT filed on **March, 30, 2001**

- 26

[illegible]




FIG. 1

MICHANISM OF CELL PROLIFERATION




FIG. 2

FUNCTION MECHANISM OF ANTITUMOR ACTIVITY




FIG. 3




FIG. 4




FIG. 5

DECLARATION AND POWER OF ATTORNEY FOR UTILITY OR DESIGN PATENT APPLICATION

☐ Submitted with Initial Filing

☒ Submitted after Initial Filing
(Surcharge (37 CFR 1.16(e)) required)

Attorney Docket No.: 33944

Application Number: 09/937,991

First Named Inventor: Hirofumi Yura

Filing Date: September 28, 2001

Group Art Unit: _____

Examiner Name: _____

As a below named inventor, I hereby declare that:

My residence, post office address, and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

“FUNCTIONALIZED GLYCOSAMINOGLYCAN POLYMER AND MEDICAL
INSTRUMENTS AND DRUGS BY USING THE SAME”

the specification of which (check only one item below)

☐ is attached hereto,

OR

☒ was filed on (MM/DD/YYYY) March 30, 2000 as United States Application Number or PCT International Application Number PCT/JP00/02012 and was amended on (MM/DD/YYYY) October 27, 2000 and March 30, 2001.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d), or 365(b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, any foreign application for patent or inventor's certificate, or any PCT international application having a filing date before that of the application on which priority is claimed.

<u>Country</u>	<u>Prior Foreign Application Number(s)</u>	<u>Foreign Filing Date (MM/DD/YYYY)</u>	<u>Priority Claimed?</u>
Japan	11/97062	April 2, 1999	Yes

I hereby claim the benefit under 35 U.S.C. 119(e) of any United States provisional application(s) listed below.

<u>Provisional Application Number(s)</u>	<u>Filing Date (MM/DD/YYYY)</u>
--	-------------------------------------

I hereby claim the benefit under 35 U.S.C. 120, of any United States application(s), or 365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of 35 U.S.C. 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

<u>U.S. Parent Application or PCT Parent Number</u>	<u>Parent Filing Date (MM/DD/YYYY)</u>	<u>Parent Patent No. (if applicable)</u>
---	--	--

As a named inventor, I hereby appoint practitioners at Customer No. 000116 as my attorneys to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith.

Address all correspondence to Customer Number 000116.

Please direct all correspondence and inquiries to Jeffrey J. Sopko at (216) 579-1700.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

1-00
(1) Inventor Name (joint): Hirofumi Yura
Signature: Hirofumi Yura
Date: December 3, 2001
Citizenship: Japan
Residence (City, State, Country): Kawasaki-shi, Kanagawa, Japan JPX
Post Office Address: 12-20-702, Hisamoto 3-chome, Takatsu-ku,
Kawasaki-shi, Kanagawa 213-0011 Japan

2-00
(2) Inventor Name (joint): Yoshio Saito
Signature: Yoshio Saito
Date: Dec. 3, 2001
Citizenship: Japan
Residence (City, State, Country): Yokohama-shi, Kanagawa, Japan JPX
Post Office Address: 6-19, Nagahama 2-chome, Kanazawa-ku
Yokohama-shi, Kanagawa 236-0011 Japan

3-00

- (3) Inventor Name (joint): Masayuki Ishihara
Signature: Masayuki Ishihara
Date: 12/10 2001
Citizenship: Japan
Residence (City, State, Country): Tachikawa-shi Tokyo, Japan
Post Office Address: 24-18, Ichibancho 6-chome, Tachikawa-shi,
Tokyo 190-0033, Japan

JPX

4-00

- (4) Inventor Name (joint): Katsuaki Ono
Signature: Katsuaki Ono
Date: Dec 10, 2001
Citizenship: Japan
Residence (City, State, Country): Tokorozawa-shi Saitama, Japan
Post Office Address: 19-501, Nishiaraimachi 17-chome, Tokorozawa-shi,
Saitama 359-0035, Japan

JPX

5-00

- (5) Inventor Name (joint): Keiichi Ishikawa
Signature: Keiichi Ishikawa
Date: Dec 10, 2001
Citizenship: Japan
Residence (City, State, Country): Tokorozawa-shi Saitama, Japan
Post Office Address: 19-2-301, Keyakidai 1-chome, Tokorozawa-shi,
Saitama 359-1118, Japan

JPX